LBP, Huawei Partner to Promote Pathology Data and Computing Power Ecological Cooperation

On May 10, 2022, Guangzhou LBP Medicine Science & Technology Co.,Ltd (688393.SH) and Huawei signed a cooperation agreement in Guangzhou to officially join the Ascend partner program, and also held a solution workshop on pathology data and arithmetic ecology cooperation. Both parties will build a pathology database based on Ascend AI and an arithmetic ecology cooperation program, including building a large model for histology AI pathology diagnosis based on MindSpore's leading technology in AI and interpretable AI, and also jointly build an independent innovative and competitive AI pathology diagnosis solution, so as to promote the industrialisation of AI in the medical field This will promote the industrialisation of AI in the medical field and support the prosperous development of the AI industry.

Tian Kunyang, vice president of Huawei Ascend computing business, said that the Ascend AI industry ecosystem is an ecosystem based on the Ascend AI basic hardware and software platform, and unites outstanding partners in the field of artificial intelligence to jointly build an artificial intelligence industry of "common construction, sharing and win-win". In medical fields such as tumor screening and pathology diagnosis, Huawei and LBP can complement each other's strengths and will work closely together to help the medical diagnosis industry move towards intelligence, enabling social development and industrial upgrading with artificial intelligence, and bringing value to human social development.

About LBP

Guangzhou LBP Medicine Science & Technology Co., Ltd. (stock code: 688393.SH) specializes in tumor screening and diagnosis, with applications mainly in pathology departments. The company has built up four series of product lines: liquid-based cytology, polymerase chain reaction, immunohistochemistry and fluorescence in situ hybridization, which cover clinical needs at different diagnostic levels from cell morphology to protein expression and gene detection in a more complete way. The company has developed 570 registered/recorded products related to pathology diagnosis, which can be used for the screening and diagnosis of many types of tumours. Some of the products have been certified by the CE European Union, British Standards Institute (BSI) and the Japanese Ministry of Health, Labour and Welfare. The company has established good cooperation with many authoritative hospitals and has been applied in many tertiary hospitals, competing with international brands and gaining wide recognition and trust from customers.